SAB Biotherapeutics Inc

+0.02 (+3.19%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)30.17M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$5.9 Million
Adjusted EPS-$0.10
See more estimates
10-Day MA$0.69
50-Day MA$0.82
200-Day MA$1.18
See more pivots

SAB Biotherapeutics Inc Stock, NASDAQ:SABS

2100 East 54th Street North, Suite 202, Sioux Falls, South Dakota 57104
United States of America
Phone: +1.605.679.6980
Number of Employees: 139


SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton and is headquartered in Sioux Falls, SD.